NCT05920096 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Grech J, Norman IJ, & Sammut R
Initial validation of measures assessing satisfaction and perceived usefulness of smoking cessation interventions among individuals with diabetes. Public Health in Practice. 2024; 7, 100487. https://doi.org/10.1016/j.puhip.2024.100487
Grech J, Norman IJ, Sammut R
Effectiveness of intensive stand-alone smoking cessation interventions for individuals with diabetes: A systematic review and intervention component analysis. Tob Induc Dis. 2023 May 10;21:57. doi: 10.18332/tid/162329. eCollection 2023.
Grech J, Norman IJ, Sammut R
Exploring the smoking cessation needs of individuals with diabetes using the Information-Motivation-Behavior Skills model. Tob Prev Cessat. 2024 Feb 2;10. doi: 10.18332/tpc/181366. eCollection 2024.
Grech J, Norman IJ, Sammut R
Helping smokers with diabetes quit: A scoping review of the interventions utilised, and the challenges and barriers to smoking cessation. Prim Care Diabetes. 2023 Apr;17(2):119-128. doi: 10.1016/j.pcd.2023.01.005. Epub 2023 Jan 19.

Feasibility Assessment of a Diabetes Specialist Nurse-led Multi-component Smoking Cessation Intervention for Individuals Living With Diabetes

Clinical trial NCT05920096 - References